Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2024

Revenue from Contract with Customer [Abstract]

Summary of Disaggregation of Revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands	Three Months Ended June 30, 2024						Six Months Ended June 30, 2024
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	12	$	—	$	12	$	23	$	—	$	23
Total Drug Products	12		—		12		23		—		23
Concentrate Products
Product Sales – Point-in-time	25,820		23,209		2,611		48,485		44,143		4,342
Total Concentrate Products	25,820		23,209		2,611		48,485		44,143		4,342
Net Revenue	$	25,832	$	23,209	$	2,623	$	48,508	$	44,143	$	4,365

In thousands	Three Months Ended June 30, 2023						Six Months Ended June 30, 2023
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	65	$	—	$	65	$	130			$	130
Total Drug Products	65		—		65		130		—		130
Concentrate Products
Product Sales – Point-in-time	18,015		16,125		1,890		36,146		32,585		3,561
License Fee – Over time	—		—		—		1,472		1,472		—
Total Concentrate Products	18,015		16,125		1,890		37,618		34,057		3,561
Net Revenue	$	18,080	$	16,125	$	1,955	$	37,748	$	34,057	$	3,691

Summary of Contract Balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.

In thousands	June 30, 2024		December 31, 2023		January 1, 2023
Accounts Receivable, net	$	10,840	$	10,901	$	6,259
Contract Liabilities, which are included in deferred license revenue	$	498	$	521	$	4,331